Bristol-Myers Beats Celgene Investors' Drug Delay Suit

By Lauren Berg · September 30, 2024, 9:24 PM EDT

A New York federal judge on Monday tossed UMB Bank's claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying shareholders $6.4...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

UMB Bank, N.A. v. Bristol-Myers Squibb Company

Case Number

Court

New York Southern

Nature of Suit

Contract: Other

Date Filed

June 02, 2021

Recent Articles By Lauren

September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
August 30, 2024
McKesson, Others To Pay Benefit Plans $300M In Opioid Deal
August 23, 2024
NY Can't Sue Groups Over Abortion 'Reversal' Ads, For Now
August 21, 2024
Fed. Circ. Won't Rethink IP Safe Harbor Case
August 21, 2024
2nd Circ. Partly Revives Life Insurance Suit Against AXA
August 09, 2024
Takeda Should Face Certified Antitrust Classes, Judge Says
August 06, 2024
Henrietta Lacks' Family Sues Novartis, Viatris Over HeLa Cells
August 02, 2024
5th Circ. Upholds Challenge To Surprise Medical Billing Rule
July 31, 2024
Wells Fargo Let Workers' Prescription Costs Soar, Suit Says